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Objective: Randomized trials and retrospective data suggest that covered balloon-expandable (CBE) stents have better
short-term patency compared with balloon-expandable bare-metal stents (BMSs) in the treatment of iliac artery disease.
This study evaluated midterm outcomes of BMSs vs CBE stents placed in the common iliac artery (CIA) for aortoiliac
occlusive disease.
Methods: All endovascular interventions for symptomatic peripheral arterial occlusive disease performed at a single
institution from 2006 to 2012 were reviewed. Patients undergoing stent placement in the CIA segment were included in
the analysis. Demographic data, TransAtlantic Inter-Society Consensus (TASC) classiﬁcation, stent type, patency, and
limb reinterventions were compared.
Results: For treatment of de novo distal aorta or CIA stenosis, 254 procedures were performed in 162 patients. BMSs
were used in 190 arteries; CBE stents were used in 64 arteries. There was no difference in age, gender, or TASC clas-
siﬁcation between the two groups. Mean follow-up was 22 6 16 months. Primary patency, assisted patency, and sec-
ondary patency were signiﬁcantly better in the BMS group. CIAs treated with covered stents were more likely at 1 year or
longer to require repeated intervention (hazard ratio, 2.5; 95% conﬁdence interval, 1.2-5.3; P [ .009). TASC classiﬁ-
cation did not predict need for reintervention in either group. Multivariate analysis revealed dual antiplatelet therapy to
be the only other factor to affect patency during long-term follow-up.
Conclusions: In this study, BMSs had signiﬁcantly better patency compared with CBE stents for treatment of aortoiliac
occlusive disease. A randomized trial comparing patency as well as restenosis rates with long-term follow-up is needed to
determine if there is any beneﬁt from use of covered stents in the aortoiliac segment. (J Vasc Surg 2014;60:337-44.)Endovascular therapy has evolved as a ﬁrst-line treat-
ment of debilitating aortoiliac occlusive disease and has
been shown to substantially improve health-related quality
of life.1 Studies comparing open surgical bypass with endo-
vascular therapy in patients with comparable disease pat-
terns have equivalent outcomes at 3 years between the
two groups.2 Open surgical treatment is maximally invasive
and carries a mortality rate of up to 4.4%.3 Additional
morbidity from aortobifemoral bypass ranges from 1% to
15%, with an infection rate of 0.5% to 5%.4,5 Endovascular
treatment avoids the physiologic stress of surgery and has
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://dx.doi.org/10.1016/j.jvs.2014.02.055Early research on aortoiliac interventions focused on an-
gioplasty vs angioplasty with bare-metal stent (BMS) place-
ment. These studies indicated that BMS placement was
associated with improved long-term patency over angio-
plasty alone6; however, BMS restenosis remains a signiﬁcant
problem. Improving long-term patency has the advantage
of reducing the need for reintervention and improving
patient satisfaction. Use of stents covered with expanded
polytetraﬂuoroethylene (ePTFE) not only supports the
treated vessel but also excludes the injured atheromatous
plaque from intraluminal macrophages that can migrate
through the stent interstices and lead to inﬂammation.7
This proposed mechanism in theory provides the potential
of improved patency because of decreased restenosis after
stent placement. This has not been substantiated by the cur-
rent literature, however.8 Studies of ePTFE-covered stents
in the infrainguinal segment have demonstrated rates of
reintervention as high as 43% at 1 year, but patency may
be improved by long-term use of dual antiplatelet agents.9
Thus far, support for the use of covered stents within
the aortoiliac segment is based on one small retrospective
review and one industry-sponsored randomized controlled
trial. The initial retrospective review consisted of only 54
patients but demonstrated a statistically improved patency
rate with the use of covered balloon-expandable (CBE)
stents (92%) compared with balloon-expandable BMSs
(72%) at 2 years for aortoiliac bifurcation disease.10 The
Covered vs Balloon Expandable Stent Trial (COBEST)
included treatment of the entire aortoiliac segment, and337
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and target vessel revascularization at 18 months. In addi-
tion, both balloon-expandable and self-expanding BMSs
were compared with CBE stents.11 The clinical signiﬁcance
of the outcomes from COBEST are uncertain and may not
accurately reﬂect how patients are treated in real-world
practice. This study therefore sought to compare the effec-
tiveness of balloon-expandable BMSs with CBE stents
implanted in the distal aorta and common iliac arteries
(CIAs) for treatment of aortoiliac occlusive disease.
METHODS
The University of California Davis maintains a retro-
spective database of all patients treated for lower extremity
arterial disease from June 2006 to December 2012. The
database collects demographic, procedural, and outcomes
data for patients who undergo endovascular or surgical
treatment. Maintenance and analysis of the database are
approved by the University of California Davis Institutional
Review Board.
Patients. All patients in the database who underwent
endovascular treatment of the CIA segment from June
2006 to December 2012 were identiﬁed. Thirteen patients
treated for recurrent disease, iliac aneurysms, or graft ste-
nosis were excluded. An additional 13 patients treated
with self-expanding stents in the CIA were also excluded.
Two patients with attempted endovascular therapy had
subsequent open surgical treatment and were also
excluded. The remaining cohort consisted of 162 patients
and 254 CIAs treated with either balloon-expandable
BMSs (n ¼ 190) or CBE stents (n ¼ 64).
Variables recorded in the database include gender,
comorbidities, preprocedure symptoms, indications for
the intervention, Rutherford classiﬁcation of disease, med-
ications, assessment of prior treatment, and results of
noninvasive vascular laboratory testing. Hyperlipidemia in-
cludes both patients with the diagnosis and those being
treated with medication. Patients on dialysis are character-
ized as having end-stage renal disease. At the time of entry
into the database, a board-certiﬁed vascular surgeon or
interventional cardiologist with peripheral arterial experi-
ence reviews all angiographic imaging to assign the appro-
priate TransAtlantic Inter-Society Consensus (TASC) II
classiﬁcation of disease and to assess runoff. For patients
treated with peripheral arterial disease, the resting ankle-
brachial index (ABI) is typically obtained preoperatively
and at clinical follow-up examinations. The typical
follow-up strategy for these patients is a duplex ultrasound
(DUS) examination or ABI within 1 to 3 months after the
procedure and at 6 and 12 months. Patients are typically
seen every 6 to 12 months in the second year and then
yearly thereafter. At each clinical visit, noninvasive testing
with DUS or ABI is obtained. DUS of the treated area is
performed if the patient’s body habitus permits. Patients
who develop clinical symptoms are reevaluated sooner
than those without symptoms.
Interventions. A board-certiﬁed vascular surgeon or
an interventional cardiologist specializing in peripheralartery disease at the University of California Davis Vascular
Center performed all interventions. The choice of CBE
stents vs BMSs was decided on a case-by-case basis at the
discretion of the treating physician. A subset of patients un-
derwent treatment of multiple arterial segments, including
the femoropopliteal segment or tibial vessels, during the in-
dex procedure. For the purpose of analysis, patients were
characterized as having undergone single-vessel (CIA only)
or multivessel (additional arterial segments treated at the
index procedure) interventions. Multivessel interventions
included both suprainguinal and infrainguinal interventions.
All treatment was performed with ﬁxed imaging under local
anesthesia with conscious sedation, except in cases in which a
hybrid surgical procedure necessitated general anesthesia.
Heparin is routinely administered to elevate the activated
clotting time above 250 seconds before intervention, and the
dose is repeated as needed throughout the course of the
procedure.
In the case of bilateral CIA interventions or distal aortic
interventions, a “kissing balloon” technique is used to
deploy the stents simultaneously. Both CBE stents and
BMSs were minimally oversized relative to the treated ar-
tery. In cases in which subintimal angioplasty was per-
formed after reentry into the aorta, the aortic bifurcation
was elevated to cover the entire area of disease. If the com-
bined stent diameter was larger than the size of the distal
aorta, smaller stents were selected and postdilated with
care. In patients with unilateral disease, the stent covered
the entire length of the stenosis or occlusion. BMSs
included the Express LD (Boston Scientiﬁc, Natick,
Mass), Omnilink (Abbott Vascular, Abbott Park, Ill), and
Genesis Palmaz (Cordis, Bridgewater, NJ). The CBE stent
used in all cases was the iCAST (Atrium Medical, Hudson,
NH) stent with an external cover of ePTFE.
All patients were prescribed aspirin after the procedure
at a dose ranging from 81 to 325 mg. Clopidogrel, at
75 mg daily, was routinely prescribed after the procedure,
with dual antiplatelet therapy continued for at least 6 weeks.
At the discretion of the treating physician, a loading dose
of 300 mg of clopidogrel was administered at the time of
the procedure. Patients receiving anticoagulation therapy
were prescribed clopidogrel for 6 weeks in addition to
the anticoagulation. After this time, patients were transi-
tioned to long-term anticoagulation and aspirin therapy.
Patients who were receiving clopidogrel before the proce-
dure were not given a loading dose, and clopidogrel was
continued indeﬁnitely.
Outcomes. Technical success was deﬁned as less than
30% residual stenosis within the CIA segment. Primary,
primary-assisted, and secondary patency were deﬁned as
recommended by the Society for Vascular Surgery guide-
lines.12 Loss of primary patency was deﬁned as any stent
that underwent reintervention to prevent thrombosis or
any stent that thrombosed primarily. The need for rein-
tervention was determined by a change in a previously
palpable pulse, recurrent symptoms, drop in the ABI
>0.15, Doppler ultrasound ﬁndings indicating a >50%
stenosis deﬁned as >100% increase in the peak systolic
Table I. Patient demographic characteristics by stent
type
Variable
BMS
(n ¼ 125),
No. (%)
CBE stent
(n ¼ 37),
No. (%) P value
Mean age 6 SD, years 65 6 11 64 6 11 .69
Male gender 58 (46) 19 (51) .73
Hypertension 97 (77) 32 (86) .34
Dyslipidemia 88 (70) 27 (73) .92
Coronary artery disease 66 (53) 17 (46) .56
Congestive heart failure 28 (22) 2 (5) .04
End-stage renal disease 14 (11) 0 .07
Diabetes mellitus 50 (40) 9 (24) .12
Stoke 25 (20) 7 (19) 1.00
Statin 86 (69) 22 (60) .39
Smoking status
Current 55 (44) 13 (35) .44
Prior 57 (46) 20 (54) .47
Never 13 (10) 4 (10) 1.00
Anticoagulation 11 (9) 1 (5) .34
Antiplatelet therapy
Aspirin 49 (39) 19 (51) .26
Clopidogrel 6 (5) 2 (5) 1.00
Aspirin þ clopidogrel 37 (30) 7 (19) .28
None 33 (26) 9 (24) .96
Clinical indication
Claudication 72 (58) 27 (73) .13
Critical limb ischemia 44 (35) 5 (14) .02
Acute limb ischemia 4 (3) 4 (10) .15
BMS, Bare-metal stent; CBE, covered balloon-expandable; SD, standard
deviation.
Table II. Comparison of CIA lesion and intervention
characteristics
N ¼ 254
CBE stents
(n ¼ 64),
No. (%)
BMS
(n ¼ 190),
No. (%) P value
Mean lesion
length 6 SD, mm
42 6 18 39 6 18 .22
TASC II classiﬁcation
A 18 (28) 55 (29) 1.00
B 21 (33) 64 (34) 1.00
C 11 (17) 46 (24) .32
D 14 (22) 25 (13) .14
Single-vessel intervention 44 (69) 118 (62) .42
Multivessel intervention 20 (31) 72 (38) .42
Suprainguinal 19 (30) 50 (26) .72
Infrainguinal 1 (1) 16 (8) .11
Both 0 (0) 6 (3) .34
BMS, Bare-metal stent; CBE, covered balloon-expandable; CIA, common
iliac artery; SD, standard deviation; TASC, TransAtlantic Inter-Society
Consensus.
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nation of these ﬁndings. Decision for reintervention was
made on a case-by-case basis. Only major amputations,
deﬁned as at the level of the ankle or more proximal, were
considered for outcomes. Minor amputations, deﬁned as
an amputation that preserved a functional foot, were
recorded but not analyzed. Overall survival was recorded
for all patients. For patients with limited follow-up, the
Social Security Death Index was used to determine mor-
tality and date of death.
Data analysis. Categorical data were described by fre-
quency and percentage and compared by c2 tests. Contin-
uous variables were described with the mean and standard
deviation. Survival, freedom from reintervention, and
patency estimates were determined by Kaplan-Meier anal-
ysis. Log-rank testing was used to compare patency esti-
mates. Multivariable analysis was used to identify risk factors
for loss of primary patency. A P value of .05 or less was
considered to be statistically signiﬁcant. All statistical anal-
ysis for this study was performed with R software (v 3.0.1).
RESULTS
Overall demographics between the two groups,
including age, hypertension, diabetes mellitus, and coro-
nary artery disease, were similar with the exception that
more patients in the BMS group had congestive heart fail-
ure (Table I). Only 10% of patients in each group were life-
long nonsmokers. One quarter of patients in both groupswere not receiving any antiplatelet treatment before the
procedure. Women represented 49% of the patients in
the CBE stent group and 54% of the patients in the BMS
group. The most common indication for treatment was
lifestyle-limiting claudication; however, a signiﬁcantly
greater number of patients in the BMS group (35% vs
15%; P ¼ .02) were treated for critical limb ischemia.
Only 10% in the BMS vs 3% in the CBE stent group
were treated for acute limb ischemia (P ¼ .15). Mean
follow-up for the cohort was 22 months (standard
deviation 6 16).
Of the 254 CIAs treated, no signiﬁcant difference be-
tween lesion length or TASC II classiﬁcation was observed
in comparing the CBE stent and BMS groups (Table II).
As expected, 30 arteries (61%) treated with covered stents
and 81 arteries (63%) treated with BMSs were for TASC A
and B disease. The CIA was the sole treated segment in 44
arteries (69%) of the CBE stent group vs 118 arteries
(62%) of the BMS group. Multivessel interventions were
performed in 20 arteries (31%) initially treated with
CBE stents. Only one of these was for concomitant
infrainguinal disease; the remaining 19 were for external
iliac artery (EIA) disease. Within the BMS group, 72
(38%) of the CIAs treated had additional arterial segments
treated during the index procedure; 22 (31%) of these
multivessel interventions were for infrainguinal occlusive
disease.
Access site complications occurred in one patient
(1.6%) treated with a CBE stent and three patients
(1.6%) treated with BMSs. Closure devices were used in
the one patient in the CBE stent group and in two of
the three patients in the BMS group. The patient in the
CBE stent group developed a hematoma that did not
require any further intervention. Two patients in the
BMS group developed pseudoaneurysms. One was treated
with ultrasound-guided compression, and the second was
treated with thrombin injection. Both resolved with these
measures. One patient in the BMS group did not have a
Table III. Patency and limb salvage by limb; survival by patient
Measure Group
Year, % (95% conﬁdence interval)
P value1 year 2 years 3 years
Primary patency Overall 90 (86-95) 84 (79-90) 81 (75-88) .008
BMS 92 (88-97) 89 (84-95) 89 (84-95)
CBE 85 (76-95) 72 (61-86) 72 (61-86)
Primary-assisted patency Overall 97 (95-100) 96 (93- 99) 96 (93-99) .04
BMS 98 (96-100) 98 (96-100) 98 (96-100)
CBE 94 (88-100) 90 (82- 99) 90 (82-99)
Secondary patency Overall 98 (94-99) 97 (93-99) 97 (87-98) .03
BMS 99 (97-100) 98 (95-100) 98 (91-100)
CBE 96 (91-100) 92 (85-99) 92 (85-99)
Limb salvage Overall 98 (96-100) 95 (92-99) 95 (92-99) .93
BMS 98 (95-100) 95 (92-99) 95 (91-99)
CBE 98 (95-100) 95 (88-100) 95 (88-100)
Survival Overall 92 (87-97) 80 (72-89) 73 (64-84) .10
BMS 90 (85-96) 75 (66-86) 71 (61-83)
CBE 97 (91-100) 97 (91-100) 81 (62-100)
BMS, Bare-metal stent; CBE, covered balloon-expandable.
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ongoing bleeding that required surgical repair.
Although 15% of the original cohort was lost to long-
term follow-up, overall primary patency at 3 years was 81%
(Table III). Limbs treated with BMSs had signiﬁcantly bet-
ter primary patency than those treated with CBE stents
(89 6 3% vs 72 6 6%; P ¼ .008; Fig 1). Secondary patency
was also signiﬁcantly better in the BMS group (98 6 1% vs
92 6 3%; P ¼ .03) compared with CBE stents (Fig 2). Five
arteries in the CBE stent group and four arteries in the
BMS group thrombosed. Although reintervention was
attempted in all but two patients with BMSs, none pro-
vided long-term patency. Two patients in each group re-
presented with acute limb ischemia when the CIA stents
thrombosed. All seven patients who had a failed reinterven-
tion went on to require open surgical bypass, and one pa-
tient needed a major amputation.
Limb salvage in both groups was 95% (P ¼ .93). Six
patients (5%) in the BMS group and two patients (5%) in
the CBE stent group required amputation. Among the pa-
tients in the BMS group who required amputation, ﬁve
were for progression of critical limb ischemia. In the
CBE stent group, amputation was required in one patient
who originally presented with acute limb ischemia. Symp-
tomatic claudication was the original presentation for two
patients, one in the BMS group and one in the CBE stent
group, which ultimately underwent amputation. The over-
all survival for the entire cohort at 3 years was 73%. Survival
was lower in the BMS group compared with the CBE stent
group (71% vs 81%); however, this was not statistically sig-
niﬁcant (P ¼ .10).
Gender, continued use of statin medications, smoking
status, bilateral CIA treatment, multivessel treatment,
lesion length, and TASC classiﬁcation were not predictive
of primary patency on multivariate analysis. In univariate
analysis, use of anticoagulation predicted long-term
patency, but this did not hold up on multivariate analysis.The only identiﬁed predictors of primary patency were
continued use of dual antiplatelet therapy at 12 months
and original indication for the procedure. Patients not tak-
ing clopidogrel and aspirin at 12 months were more likely
to undergo reintervention or to experience thrombosis at
3 years (hazard ratio, 4.25; P ¼ .003). In addition to
dual antiplatelet therapy, original indication for the proce-
dure predicted loss of primary patency. Patients treated for
claudication were more likely to require reintervention at
3 years than those treated for critical limb ischemia (hazard
ratio, 2.6; 95% conﬁdence interval, 1.14-6.09; P ¼ .02).
DISCUSSION
This study represents the largest reported comparison
of balloon-expandable BMSs to CBE stents in the CIA
for the treatment of aortoiliac occlusive disease. The main
ﬁnding was that BMSs were associated with improved pri-
mary and secondary patency compared with CBE stents.
COBEST, currently the only randomized controlled
trial of the two stent types, randomized 168 limbs, but
the primary outcome was binary restenosis and not primary
patency. In addition, the study did not separate CIAs and
EIAs in the analysis.11 Other studies of patients with CIA
disease have shown primary patency rates that range from
63% to 86% at 4 years.14,15 Our study showed similar re-
sults, with an overall 3-year primary patency of 81%. In a
study of 54 patients treated with bilateral kissing stents
for aortoiliac bifurcation disease, Sabri showed the primary
patency of covered stents to be 92% compared with 62% in
the BMS group.10 The low primary patency of BMSs in
this study raises questions about including deployment of
stents sized below 8 mm in diameter and extending
BMSs more than 1 cm above the aortic bifurcation. In
COBEST as well as in other trials, BMSs that extended
more than 1 cm above the bifurcation had poorer out-
comes. This suggests that for the kissing technique or in
treatment of bilateral disease, CBE stents may be more
Fig 1. Primary patency of bare-metal (BM) stents (89% 6 3%)
compared with covered balloon-expandable (CBE) stents (72%6 6%)
in the common iliac artery (CIA) (P ¼ .008).
Fig 2. Secondary patency of bare-metal (BM) stents (98% 6 1%)
compared with covered balloon-expandable (CBE) stents (92%6 3%)
in the common iliac artery (CIA) by limb (P ¼ .03).
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BMSs had worse outcomes than those with CBE stents,
although an analysis of the distance that stents extended
into the aorta for bilateral disease was not performed.
The secondary patency of CBE stents in our study was
97% with follow-up to 3 years. The lower primary patency
and high primary-assisted and secondary patency likely
reﬂect the aggressive use of routine DUS screening and
willingness to intervene early in identiﬁed stenosis.
Although routine postprocedure evaluation has been
questioned because of the added cost, the difference in
secondary patency rates may very well support its use.
All patients in our study who had an intervention before
stent thrombosis remained patent after treatment. The
signiﬁcant difference in improved secondary patency of
BMSs compared with CBE stents may be the result of
higher numbers of patients treated with BMSs. Gandini
et al found that long-term secondary patency for stents
in the aortoiliac segment was 90% at 5 years but
decreased to 78% at 10 years.16 They used a follow-up
schedule of 1, 3, 6, and 12 months for the ﬁrst year
and then yearly after that, similar to our study. Although
DUS was the primary mode to detect restenosis, they
also routinely obtained computed tomography angiog-
raphy at 6 and 12 months or if DUS showed any evi-
dence of restenosis. In most cases, the CIA segment
can be imaged adequately. In patients in whom body
habitus precluded DUS, a drop in ABI of more than
0.15 has been shown to be predictive of restenosis and
potential thrombosis. The increased radiation associated
with computed tomography angiography does not sup-
port its use for surveillance imaging.
Surgery has traditionally been recommended for pa-
tients with TASC C and D lesions because of the
improved durability of the intervention.17 However,
several studies have shown that patients with TASC C
and D iliac lesions do better with primary stenting. Pri-
mary patency rates in these patients range from 72% to
89% at 3 years, with secondary patency rates between83% and 93%.6,18,19 COBEST demonstrated that pa-
tients with TASC C and D disease treated with covered
stents had lower binary restenosis than those treated
with BMSs, although the study was not adequately pow-
ered for subgroup analysis. In that study, 51% of the pa-
tients in the covered stent group and 43% in the BMS
group had advanced disease. In our study, TASC C
and D lesions represented only 39% of the limbs treated
with covered stents and 37% of the BMS group. These
lower numbers may not be adequate to detect a differ-
ence in patency on univariate analysis.
EIA disease tends to be long-segment disease, is best
treated completely, and may require multiple overlapping
stents. Gandini et al retrospectively reviewed 138 patients
with aortoiliac disease and found that stents in the EIA
had worse patency than those in the CIA.16 In addition,
when both the CIA and EIA were treated simultaneously,
patency was signiﬁcantly lower than when the CIA was the
isolated treatment segment. We analyzed our population
by isolated treatment of the CIA segment compared with
multivessel treatment of other arterial segments during
the initial procedure, whether suprainguinal or infraingui-
nal. No difference was found in the primary patency of
the CBE stent or BMS when the EIA was also treated at
the same time. This may reﬂect our use of newer, long, sin-
gle, self-expanding stents in the EIA segment compared
with prior studies, in which multiple CBE stents or BMSs
were required and self-expanding stents were not as
conformable in the tortuous EIA.
There was no difference in limb salvage between the
two groups in this study. Other studies have demonstrated
an amputation rate after iliac artery stenting as high as
12%.20 The overall amputation rate in this study was 5%.
However, in terms of absolute numbers, more patients in
the BMS group underwent a major amputation. The 3%
amputation rate in the BMS group is likely to be due to
initial treatment indication rather than to stent thrombosis.
More patients in the BMS group were treated for critical
limb ischemia. Of the eight limbs amputated during the
JOURNAL OF VASCULAR SURGERY
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stents. The one patient whose BMS thrombosed was orig-
inally treated for symptomatic claudication with bilateral
CIA stents. The patient re-presented with stent thrombosis
and underwent surgical bypass. The amputation occurred
1 year after surgical treatment.
Women represented 49% of the patients in the CBE
stent group and 54% of those in the BMS group. Gender
has been associated with worse outcomes after endovascu-
lar treatment in both the femoropopliteal region and the
iliac arteries. This has been most pronounced in women
with critical limb ischemia. Using administrative data,
Goode et al evaluated more than 23,000 iliac interventions
performed on the iliac segment in England during a 5-year
period. On multivariate analysis, they found that women
had worse outcomes than men (odds ratio, 4.98 [2.09-
13.25]).21 Our study found no difference in primary or
secondary patency of CBE stents or BMSs in the CIAs
on the basis of gender. The group was further stratiﬁed
to compare only the 133 patients with critical limb
ischemia. Again, gender was not predictive of loss of pri-
mary or secondary patency.
The use of dual antiplatelet therapy was one of the only
factors found to improve the overall primary patency. In a
study of 87 limbs treated with stent grafts in the femoropo-
pliteal segment, Johnston et al found that continued use of
dual antiplatelet therapy was protective against major
adverse limb events.9 This study focused on the femoropo-
pliteal segment, which is subjected to many different forces
with movement. The CIA segment does not move in the
same manor, but our results would also support continued
use of dual antiplatelet therapy.
Our studyhas several limitations. First, this study is retro-
spective, and although attempts were made to limit the pa-
tient population to a homogeneous group by excluding
patients not treated speciﬁcally for aortoiliac occlusive dis-
ease, subtle factors that inﬂuenced stent selection may not
have been recorded. Moreover, there are markedly more
patients in the BMS group, and this difference persists
throughout the follow-up period. The statistical difference
in outcomes could be the result of the unequal cohorts and
smaller size at later dates of follow-up. Our facility has
on hand advanced reentry equipment that may make our
technical success rate potentially higher than that of other fa-
cilities.Only two patients in the original cohort were not suc-
cessfully treated and went on to require open surgical
treatment. Finally, 15% of patients in our study were lost to
follow-up, and these patients could represent signiﬁcant
stent failures or patients who needed surgical revision.
CONCLUSIONS
In this single-center retrospective experience, BMSs
were found to be superior to CBE stents for the treatment
of CIA disease at 3 years. Currently, the DISCOVER trial
(Dutch Iliac Stent Trial: COVERed balloon-expandable vs
uncovered balloon-expandable stents in the common iliac
artery) is randomizing patients with iliac disease to deﬁni-
tively answer the question of whether covered stents inthe CIAs are better than BMSs. Our results are in contrast
to reports that show CBE stents are superior to BMSs, and
at this time there is not sufﬁcient evidence to support the
use of more costly CBE stents for treatment of atheroscle-
rotic disease of the CIA.
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thank the program committee for the opportunity to discuss this
paper. And, thank you to Dr Humphries for providing the manu-
script to me prior to the meeting.
Dr Humphries and her colleagues at UC Davis have per-
formed a retrospective analysis of their experience using balloon-
expandable stents for the treatment of common iliac artery disease.
They have compared their experience with covered balloon-
expandable and bare-metal balloon expandable stents in 162
patients and 254 arteries treated over a 6.5-year period.
The vast majority (75%) of these were patients treated with
balloon-expandable bare-metal stents. Only 25% of patients were
treated with covered stents. They had a mean follow-up of
22 months. And, as she showed, a signiﬁcantly higher proportion
of patients in the bare metal stent group presented with CLI.
Their results showed that primary, assisted-primary, and sec-
ondary patency were signiﬁcantly better for bare-metal stents
compared with covered stents. This was irrespective of TASC clas-
siﬁcation, lesion length, or adjunctive procedures performed above
or below the inguinal crease. Mortality and limb salvage were not
statistically different between the two groups. However, I was
saddened to see that two patients who initially presented with clau-
dication ended up requiring amputations.
Their results are in direct contrast to multiple other studies
which have shown improved outcomes in the common iliac
segment using covered BE stents. The COBEST trial was a pro-
spective, multicenter, randomized controlled trial published in
JVS in 2011 from Australia that showed signiﬁcantly less restenosis
and fewer reinterventions in the group treated with covered stents.
Their subgroup analysis showed that patients with TASC C and D
lesions actually did the best with covered stents. Similar results
were found in other series as well. So, I have just fourteen ques-
tions for you. No, actually I only have four.
First, you found an equally small number of stents in each
group that experienced thrombosis. If that is true, then what
was the primary method of failure in the covered stent group?
Were these lesions at the proximal or distal ends of the stent grafts
or de novo lesions? And, since you were following these patients
closely with DUS, were their differences in ﬂow velocities on
follow-up duplex that could have identiﬁed those stents at risk of
failure?
Second, more patients in the bare-metal group underwent
concomitant SFA interventions. Despite the fact that this did not
quite reach statistical signiﬁcance, is it possible that these patients
had improved outﬂow that accounted for the improved patency?
Similarly, do you have any information on the degree of disease
in the hypogastric or external iliac artery that could be of
relevance?
Third, how do you account for the completely opposite results
from the ﬁndings of other studies that show superior patency rates
of covered stents in this population? Typically, we see patients
with CLI have worse outcomes than patients with claudication;however, you had much higher percentage of CLI patients that
received bare-metal stents. The COBEST trial had less that 6%
of self-expanding bare-metal stents in their cohort, so that is not
a great explanation for the discrepant ﬁndings.
Finally, what is your recommendation for me the next time I
succeed in recannalizing a TASC D CIA lesion? Should I follow
your data or those of many others?
I enjoyed reading your paper and again appreciate the oppor-
tunity to discuss this paper.
Dr Misty D. Humphries. Thank you for the questions. I will
address them in the order presented.
We did not assess the speciﬁc failure mode for each either
group, although those patients with repeat interventions have an-
giograms that can be reviewed. The presumed mechanism for fail-
ure for covered stents is thought to be at the ends of the stents vs
bare-metal stents, which develop diffuse stenosis throughout the
stent. Although most patients are followed with duplex ultrasound,
documentation of the speciﬁc mode of failure was not recorded. As
a follow-up to this work, we would like to investigate the mecha-
nism of failure for both stent types as well as the difference between
stent restenosis and patency.
As far as differences based on outﬂow disease, we attempted to
characterize procedures as multiple intervention procedures
involving the supra- and/or infrainguinal region vs single-interven-
tion procedures involving only the common iliac segment. No dif-
ference was found in the outcomes for patients with multiple
interventions compared to those with only single interventions,
but we did not look at all angiograms to speciﬁcally assess the
femoral outﬂow. Unfortunately, we do not have angiographic eval-
uation of the SFA in all patients. We could go back to evaluate the
internal iliac arteries, but in all these patients, the external iliac ar-
teries were either treated or patent. Therefore, utility of reporting
the internal iliac arteries speciﬁcally is unclear. As far as the degree
of disease in the iliac arteries, the TASC class reported here is based
on the iliac angiography and we found no difference in the out-
comes with worsening TASC classiﬁcation.
Our work is in opposition to the only RCT on covered vs
bare-metal stents, but we evaluated the group by patency. Other
studies have looked at binary restenosis and used duplex ultra-
sound criteria that may or may not be considered a stenosis in a
stented region by those of us in this room. Covered stents develop
less binary restenosis according to the COBEST trial, but not all
patients get a reintervention immediately when they develop a
duplex identiﬁed stenosis that is >250cm/sec. A stenosis at this
level may be watched for progression or the development of recur-
rent symptoms before a patient gets a reintervention. Our work
presents pragmatic results of bar- metal and covered stents. We
are showing that in a typical practice, bare-metal stents are used
more frequently and the patency is not worse than covered stents.
Finally, the next time you recanalize a stenosis for a TASC D
CIA lesion, consider my work as a guide for you but not a deﬁn-
itive answer. I do not think I can tell you to use a covered stent or a
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ness of covered and uncovered stents, which we are working on.
Patency captures the initial reintervention the patient has after
stent placement, but if two or three interventions are needed to
maintain the patency for a bare-metal stent, the lower cost may
not be justiﬁed. How much do these repeat procedures cost? We
don’t know the answers to these questions and we need to in order
to make a deﬁnitive recommendation about what stents should be
used in the common iliac arteries and all peripheral arteries. Our
work simply shows that with regard to patency, bare-metal stentsare not necessarily worse than covered. It also pushes the question
of how do we translate data from randomized control trials into
practice, and whether we should use data from trials that consider
outcomes we may not agree with to inﬂuence our practice. The
DISCOVER trial that is ongoing in The Netherlands may be
able to answer the question of which stents develop stenosis, but
again, these types of explanatory trials can’t always translate into
the pragmatic setting that we practice in. Until a more comprehen-
sive approach to evaluating restenosis, patency, reinterventions,
and cost effectiveness is available, my practice will not change.
